Squarepoint’s CorMedix CRMD Stock Holding History

Squarepoint’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Sell	207,378 -77,692	-27%	-$614K	﹤0.01%	2498
2026 Q1	$1.94M	Sell	285,070 -147,145	-34%	-$1.09M	﹤0.01%	2201
2025 Q4	$5.03M	Buy	432,215 +243,136	+129%	+$2.69M	0.01%	1445
2025 Q3	$2.2M	Sell	189,079 -101,753	-35%	-$1.23M	﹤0.01%	2016
2025 Q2	$3.58M	Buy	290,832 +224,412	+338%	+$2.48M	﹤0.01%	1685
2025 Q1	$409K	Buy	+66,420	New	+$688K	﹤0.01%	3483
2024 Q1	–	Sell	-77,066	Closed	-$290K	–	4127
2023 Q4	$290K	Buy	+77,066	New	+$265K	﹤0.01%	3382
2023 Q2	–	Sell	-26,280	Closed	-$109K	–	3628
2023 Q1	$109K	Buy	+26,280	New	+$108K	﹤0.01%	2957
2021 Q2	–	Sell	-22,275	Closed	-$223K	–	3300
2021 Q1	$223K	Buy	+22,275	New	+$234K	﹤0.01%	2636
2019 Q2	–	Sell	-17,142	Closed	-$162K	–	2409
2019 Q1	$162K	Buy	+17,142	New	+$154K	﹤0.01%	1980
2018 Q1	–	Sell	-2,940	Closed	-$7K	–	1757
2017 Q4	$7K	Buy	+2,940	New	+$8.44K	﹤0.01%	2043
2016 Q3	–	Sell	-9,160	Closed	-$91K	–	1047
2016 Q2	$91K	Buy	+9,160	New	+$139K	0.01%	987

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Squarepoint's CRMD Position: Q2 2026 in Review

Squarepoint reduced its CorMedix (CRMD) stake by 27% in Q2 2026, selling an estimated $614K and leaving 207,378 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

Squarepoint first reported a position in CRMD in Q2 2016 and has held it in 12 quarters since. The position peaked at $5.03M in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Squarepoint held 207,378 shares of CorMedix worth $1.63M as of Q2 2026.
Squarepoint sold 77,692 CorMedix shares in Q2 2026, an estimated $614K.
CorMedix made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2498 holding.
Squarepoint first reported a position in CorMedix in Q2 2016 and has held it in 12 quarters since.
Squarepoint's CorMedix position peaked at $5.03M in Q4 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.